These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31478786)

  • 61. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.
    Chang WL; Kao CY; Wu CT; Huang AH; Wu JJ; Yang HB; Cheng HC; Sheu BS
    Helicobacter; 2012 Jun; 17(3):210-5. PubMed ID: 22515359
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence and mechanisms of quinolone resistance among selected nontyphoid Salmonella isolated from food animals and humans in Korea.
    Tamang MD; Nam HM; Kim A; Lee HS; Kim TS; Kim MJ; Jang GC; Jung SC; Lim SK
    Foodborne Pathog Dis; 2011 Nov; 8(11):1199-206. PubMed ID: 21877929
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quinolone Resistance Mechanisms Among Salmonella enterica in Malaysia.
    Thong KL; Ngoi ST; Chai LC; Teh CS
    Microb Drug Resist; 2016 Jun; 22(4):259-72. PubMed ID: 26683630
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital.
    Zhang H; Zheng L; Zhao J; Ding S; Xia Y
    J Med Microbiol; 2019 Feb; 68(2):206-210. PubMed ID: 30632961
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
    Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Apigenin as an anti-quinolone-resistance antibiotic.
    Morimoto Y; Baba T; Sasaki T; Hiramatsu K
    Int J Antimicrob Agents; 2015 Dec; 46(6):666-73. PubMed ID: 26526895
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of Mismatch Amplification Mutation Assay PCR and PCR-Restriction Fragment Length Polymorphism for Detection of Major Mutations in gyrA and parC of Escherichia coli Associated with Fluoroquinolone Resistance.
    Jazeela K; Chakraborty G; Shetty SS; Rohit A; Karunasagar I; Vijaya Kumar D
    Microb Drug Resist; 2019; 25(1):23-31. PubMed ID: 30036132
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium.
    Bogaerts P; Berhin C; Nizet H; Glupczynski Y
    Helicobacter; 2006 Oct; 11(5):441-5. PubMed ID: 16961806
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
    Shigemura K; Shirakawa T; Okada H; Hinata N; Acharya B; Kinoshita S; Kofuku T; Kawabata M; Kamidono S; Arakawa S; Gotoh A
    Sex Transm Dis; 2004 Mar; 31(3):180-4. PubMed ID: 15076932
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S; Tandon V
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan.
    Hung KH; Sheu BS; Chang WL; Wu HM; Liu CC; Wu JJ
    Helicobacter; 2009 Feb; 14(1):61-5. PubMed ID: 19191898
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis.
    Shultz TR; White PA; Tapsall JW
    Antimicrob Agents Chemother; 2005 May; 49(5):1753-60. PubMed ID: 15855492
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
    Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
    J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.